Jade Biosciences, Inc. (JBIO) earnings date
Mar 26, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Nov 13, 2026 | before open | 44 | 8-K |
| Q2 FY2026 | Mon, Aug 10, 2026 | before open | 41 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Fri, Mar 6, 2026 | before open | 65 | 8-K |
| Q3 FY2025 | Fri, Nov 14, 2025 | before open | 45 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | after close | 44 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | after close | 31 | 8-K |
| Q1 FY2024 | Mon, May 13, 2024 | after close | 43 | 8-K |
What they guided beta
| Q3 FY2026 | "JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026" exhibit |
| Q3 FY2026 | "JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027" exhibit |
| Q3 FY2026 | "JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027" exhibit |
| Q3 FY2026 | "JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027" exhibit |
| Q3 FY2026 | "Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028" exhibit |
| Q2 FY2026 | "Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027" exhibit |
| Q2 FY2026 | "Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027" exhibit |
| Q2 FY2026 | "Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027" exhibit |
| Q2 FY2026 | "JADE301, a potentially best-in-class, half-life–extended anti-IFN-ß for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027" exhibit |
| Q2 FY2026 | "Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/JBIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/JBIO
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/JBIO/"><img src="https://veritasdata.dev/embed/JBIO.svg" alt="JBIO earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/JBIO/)
Script
<script async src="https://veritasdata.dev/embed/JBIO.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/JBIO"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.